"Sentiment will take the stock higher. I think it trades up to that $30 level we saw back in March because the headlines probably—and I'm not trying to be an alarmist—but the headlines are probably not going to get better before they get worse," Private Advisor Group's Guy Adami said. "You have to assume that this stock, just sentiment and momentum will take this stock to $30 in my opinion."
On CNBC's "Fast Money," Brian Kelly of Brian Kelly Capital agreed, regardless of whether the as-yet experimental drug proves to be effective against Ebola in humans.
"I think that the sentiment alone, the sentiment alone—that's not talking about whether it works or not—is going to be something that keeps these stocks higher," he said. "The other place I would look is the cocoa market. Fifty percent of the world's cocoa comes from West Africa."
The U.S. Centers for Disease Control confirmed one case of Ebola in a patient being treated at Texas Health Presbyterian Hospital of Dallas.
The CDC previously said that up to 1.4 million people in West Africa could be infected by January 2015.
More than 6,500 cases have been confirmed since the first outbreak was identified in Guinea six months ago.
Karen Finerman of Metropolitan Capital Advisors said that airline stocks could see an effect from the Ebola news, as well as videoconferencing companies such as Polycom.
"It's a leap," she said. "I understand that, but just trying to think through what could be the ramifications."